Dr. Habib is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
101 The City Dr S
Orange, CA 92868Phone+1 714-456-7890Fax+1 714-456-8995
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Fellowship, Neuromuscular Medicine (Neurology), 2009 - 2010
- New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 2004 - 2008
- Aga Khan Medical CollegeClass of 2001
Certifications & Licensure![](https://directory.doximity.com/assets/icons/icon-help-e9f0b148a1e6d1f037dde9f26f025c36bd7c99fd4fe31fd76792996fa2aa5e66.svg)
- CA State Medical License 2010 - 2026
- WA State Medical License 2010 - 2019
- NY State Medical License 2008 - 2012
- American Board of Psychiatry and Neurology Neurology
- American Board of Psychiatry and Neurology Neuromuscular Medicine
Publications & Presentations
PubMed
- 1 citationsSafety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.Ali A Habib, Chongbo Zhao, Inmaculada Aban, Marcondes Cavalcante França Jr, Jorge Gustavo José
The Lancet. Neurology. 2025-02-01 - The Economic Burden of Myasthenia Gravis (MG): A Survey of Affected People and Their Families.Kathleen Yoder, Rachael Burris, Sujatha Gurunathan, Glenn Phillips, Kathy Perez
Muscle & Nerve. 2025-02-01 - Time to response with ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gra...Ali A Habib, Michael Benatar, Tuan Vu, Andreas Meisel, Shahram Attarian
European Journal of Neurology. 2024-12-01
Press Mentions
- Phase 1 Trial of NKX019 Cell Therapy in gMG Patients Cleared to OpenDecember 10th, 2024
- Nkarta Announces IND Clearance of Investigator-Sponsored Trial in Myasthenia Gravis and Opening of Enrollment for Ntrust-2December 6th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: